{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T07:09:19Z","timestamp":1788592159357,"version":"build-2803163510"},"reference-count":164,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Positron emission tomography (PET) is a molecular imaging technique that exploits the \u03b2+ decay of selected radionuclides to enable non-invasive in vivo investigation of biochemical and physiological processes, including early and subclinical disease alterations. Radiotracers are designed to bind specific molecular targets with high affinity and selectivity. Among the targets to which PET devotes increasing attention are G protein-coupled receptors (GPCRs)\u2014the largest class of transmembrane receptors\u2014which orchestrate a wide spectrum of biological outcomes and are widely implicated in human disease. Objectives: This review analyzes patents published between 2020 and 2025 focusing on GPCR-targeted PET radiotracers, highlighting design strategies, radionuclide selection, and translational perspectives across oncology, central nervous system (CNS) disorders, and inflammatory diseases. Results: Patent activity shows that most GPCR-targeted PET tracers are derived from validated ligands adapted for imaging while preserving affinity and selectivity. Oncology patents mainly favor peptide-based or modular metal\u2013chelator platforms enabling radionuclide flexibility and theranostic extension, whereas CNS tracers rely on drug-like small molecules optimized under strict ADME and blood\u2013brain barrier constraints. Increasing emphasis on non-orthosteric, function-sensitive, and dual-targeting approaches reflects a shift toward interrogating GPCR signaling states, while inflammatory indications remain comparatively underrepresented despite clear biological foundations. Conclusions: Current patent trends consolidate GPCR-targeted PET tracers as well-established diagnostic tools while progressively expanding their clinical utility, both as platforms supporting translational research\u2014informing mechanistic insight and drug development\u2014and as components of emerging theranostic strategies across multiple disease areas.<\/jats:p>","DOI":"10.3390\/ph19060900","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T07:43:02Z","timestamp":1780904582000},"page":"900","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advances in GPCR-Targeted PET Radiotracer Patents (2020\u20132025)"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9709-766X","authenticated-orcid":false,"given":"Rebecca","family":"Ferrisi","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Medicinal Chemistry Section \u201cPietro Pratesi\u201d, University of Milan, Via L. Mangiagalli 25, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6038-0738","authenticated-orcid":false,"given":"Clara","family":"Mocchetti","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Medicinal Chemistry Section \u201cPietro Pratesi\u201d, University of Milan, Via L. Mangiagalli 25, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4796-5539","authenticated-orcid":false,"given":"Alessia","family":"Cazzaniga","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Medicinal Chemistry Section \u201cPietro Pratesi\u201d, University of Milan, Via L. Mangiagalli 25, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0236-0662","authenticated-orcid":false,"given":"Marco","family":"De Amici","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Medicinal Chemistry Section \u201cPietro Pratesi\u201d, University of Milan, Via L. Mangiagalli 25, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1877-8331","authenticated-orcid":false,"given":"Claudio","family":"Papotto","sequence":"additional","affiliation":[{"name":"Tecnomed Foundation, University of Milan-Bicocca, Via G. Pergolesi 33, 20900 Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7383-1484","authenticated-orcid":false,"given":"Clelia","family":"Dallanoce","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Medicinal Chemistry Section \u201cPietro Pratesi\u201d, University of Milan, Via L. Mangiagalli 25, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1021\/cr0782426","article-title":"Molecular Imaging with PET","volume":"108","author":"Ametamey","year":"2008","journal-title":"Chem. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"9226","DOI":"10.1073\/pnas.97.16.9226","article-title":"Positron Emission Tomography Provides Molecular Imaging of Biological Processes","volume":"97","author":"Phelps","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"8998","DOI":"10.1002\/anie.200800222","article-title":"Synthesis of11 C,18 F,15 O, and13 N Radiolabels for Positron Emission Tomography","volume":"47","author":"Miller","year":"2008","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"13873","DOI":"10.1021\/acs.joc.1c01474","article-title":"18 F-Fluorination: Challenge and Opportunity for Organic Chemists","volume":"86","author":"Halder","year":"2021","journal-title":"J. Org. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.nucmedbio.2010.04.185","article-title":"Fluorine-18 Radiopharmaceuticals beyond [18F]FDG for Use in Oncology and Neurosciences","volume":"37","author":"Coenen","year":"2010","journal-title":"Nucl. Med. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1021\/acs.jmedchem.0c01053","article-title":"Carbon-11: Radiochemistry and Target-Based PET Molecular Imaging Applications in Oncology, Cardiology, and Neurology","volume":"64","author":"Goud","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Rong, J., Haider, A., Jeppesen, T.E., Josephson, L., and Liang, S.H. (2023). Radiochemistry for Positron Emission Tomography. Nat. Commun., 14.","DOI":"10.1038\/s41467-023-36377-4"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.2147\/OTT.S140671","article-title":"Theranostics in Nuclear Medicine Practice","volume":"10","author":"Yordanova","year":"2017","journal-title":"OncoTargets Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00259-024-06915-3","article-title":"EANM\/SNMMI Guideline\/Procedure Standard for [18F]FDG Hybrid PET Use in Infection and Inflammation in Adults v2.0","volume":"52","author":"Abikhzer","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s00259-004-1687-6","article-title":"[18F]FLT-PET in Oncology: Current Status and Opportunities","volume":"31","author":"Been","year":"2004","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2967\/jnumed.111.096859","article-title":"Performance of18 F-Fluoro-Ethyl-Tyrosine (18 F-FET) PET for the Differential Diagnosis of Primary Brain Tumor: A Systematic Review and Metaanalysis","volume":"53","author":"Dunet","year":"2012","journal-title":"J. Nucl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jbo.2015.08.002","article-title":"The Role of 18F\u2013NaF PET\/CT in Metastatic Bone Disease","volume":"4","author":"Araz","year":"2015","journal-title":"J. Bone Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"862","DOI":"10.2967\/jnumed.110.076471","article-title":"Feasibility of 18F-Sodium Fluoride PET\/CT for Imaging of Atherosclerotic Plaque","volume":"51","author":"Derlin","year":"2010","journal-title":"J. Nucl. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.prro.2017.07.011","article-title":"Prostate Cancer\u2013Specific PET Radiotracers: A Review on the Clinical Utility in Recurrent Disease","volume":"8","author":"Evans","year":"2018","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"692","DOI":"10.2967\/jnumed.124.269163","article-title":"18 F-Fluoroestradiol PET\/CT for Predicting Benefit from Endocrine Therapy in Patients with Estrogen Receptor\u2013Positive Breast Cancer: A Systematic Review and Metaanalysis","volume":"66","author":"Parihar","year":"2025","journal-title":"J. Nucl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s13139-022-00748-4","article-title":"Prospective F-18 FDOPA PET Imaging Study in Human PD","volume":"56","author":"Dhawan","year":"2022","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2967\/jnumed.120.252254","article-title":"Brain Tau Imaging: Food and Drug Administration Approval of 18 F-Flortaucipir Injection","volume":"61","author":"Mattay","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Z\u00fcrcher, N.R., Walsh, E.C., Phillips, R.D., Cernasov, P.M., Tseng, C.-E.J., Dharanikota, A., Smith, E., Li, Z., Kinard, J.L., and Bizzell, J.C. (2021). A Simultaneous [11C]Raclopride Positron Emission Tomography and Functional Magnetic Resonance Imaging Investigation of Striatal Dopamine Binding in Autism. Transl. Psychiatry, 11.","DOI":"10.1101\/2020.08.10.20172197"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2147\/CIA.S132884","article-title":"11C-PIB PET Imaging Reveals That Amyloid Deposition in Cases with Early-Onset Alzheimer\u2019s Disease in the Absence of Known Mutations Retains Higher Levels of PIB in the Basal Ganglia","volume":"12","author":"Youn","year":"2017","journal-title":"Clin. Interv. Aging"},{"key":"ref_20","first-page":"33","article-title":"The Clinical Use of PET with 11C-Acetate","volume":"2","author":"Grassi","year":"2012","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4103\/ijnm.ijnm_16_25","article-title":"Potential Role of 13N-NH3 Cardiac PET in Monitoring Treatment Response in Patients with Microvascular Angina","volume":"40","author":"Singh","year":"2025","journal-title":"Indian J. Nucl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1053\/j.semnuclmed.2023.08.002","article-title":"[15O]H2O PET: Potential or Essential for Molecular Imaging?","volume":"54","author":"Slart","year":"2024","journal-title":"Semin. Nucl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2967\/jnumed.109.066738","article-title":"124I PET-Based 3D-RD Dosimetry for a Pediatric Thyroid Cancer Patient: Real-Time Treatment Planning and Methodologic Comparison","volume":"50","author":"Hobbs","year":"2009","journal-title":"J. Nucl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1007\/s00259-011-1769-1","article-title":"Three-Dimensional Radiobiological Dosimetry (3D-RD) with 124I PET for 131I Therapy of Thyroid Cancer","volume":"38","author":"Sgouros","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_25","first-page":"311","article-title":"Somatostatin Receptor PET Ligands\u2014The next Generation for Clinical Practice","volume":"8","author":"Pauwels","year":"2018","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/RLU.0000000000002003","article-title":"[44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate Carcinoma","volume":"43","author":"Khawar","year":"2018","journal-title":"Clin. Nucl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Krasnovskaya, O.O., Abramchuck, D., Erofeev, A., Gorelkin, P., Kuznetsov, A., Shemukhin, A., and Beloglazkina, E.K. (2023). Recent Advances in 64Cu\/67Cu-Based Radiopharmaceuticals. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119154"},{"key":"ref_28","first-page":"40","article-title":"Synthesis and Evaluation of [64Cu]PSMA-617 Targeted for Prostate-Specific Membrane Antigen in Prostate Cancer","volume":"7","author":"Cui","year":"2017","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_29","first-page":"426","article-title":"The Value of 68Ga-DOTATATE PET\/CT in Diagnosis and Management of Neuroendocrine Tumors Compared to Current FDA Approved Imaging Modalities: A Review of Literature","volume":"4","author":"Mojtahedi","year":"2014","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2967\/jnumed.120.260455","article-title":"68Ga-PSMA-11 NDA Approval: A Novel and Successful Academic Partnership","volume":"62","author":"Carlucci","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s12350-017-0855-6","article-title":"Clinical Performance of Rb-82 Myocardial Perfusion PET and Tc-99m-Based SPECT in Patients with Extreme Obesity","volume":"26","author":"Harnett","year":"2019","journal-title":"J. Nucl. Cardiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1007\/s00259-004-1561-6","article-title":"Pre-Therapeutic Dosimetry and Biodistribution of 86Y-DOTA-Phe1-Tyr3-Octreotide versus 111In-Pentetreotide in Patients with Advanced Neuroendocrine Tumours","volume":"31","author":"Helisch","year":"2004","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s11307-016-0951-z","article-title":"[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer","volume":"18","author":"Laforest","year":"2016","journal-title":"Mol. Imaging Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"151","DOI":"10.7150\/thno.37098","article-title":"ImmunoPET Predicts Response to Met-Targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors","volume":"10","author":"Escorcia","year":"2020","journal-title":"Theranostics"},{"key":"ref_35","unstructured":"Kapoor, M., Heston, T.F., and Kasi, A. (2026, May 20). PET Scanning, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559089\/."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"9232","DOI":"10.1021\/jm5001858","article-title":"Positron Emission Tomography in CNS Drug Discovery and Drug Monitoring","volume":"57","author":"Piel","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nrd.2017.178","article-title":"Trends in GPCR Drug Discovery: New Agents, Targets and Indications","volume":"16","author":"Hauser","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.molmed.2010.11.004","article-title":"Therapeutic Potential of \u03b2-Arrestin- and G Protein-Biased Agonists","volume":"17","author":"Whalen","year":"2011","journal-title":"Trends Mol. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1124\/mol.117.111062","article-title":"G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs?","volume":"93","author":"Sriram","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Krishna Deepak, R.N.V., Verma, R.K., Hartono, Y.D., Yew, W.S., and Fan, H. (2021). Recent Advances in Structure, Function, and Pharmacology of Class A Lipid GPCRs: Opportunities and Challenges for Drug Discovery. Pharmaceuticals, 15.","DOI":"10.3390\/ph15010012"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1042\/BST20210431","article-title":"Structure Determination of GPCRs: Cryo-EM Compared with X-Ray Crystallography","volume":"49","author":"Tate","year":"2021","journal-title":"Biochem. Soc. Trans."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.tips.2019.04.001","article-title":"GPCRomics: An Approach to Discover GPCR Drug Targets","volume":"40","author":"Insel","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1111\/bph.70102","article-title":"GPCR-G Protein Signalling and Its Mutational Landscape in Cancer\u2014Driver or Passenger","volume":"182","author":"Feng","year":"2025","journal-title":"Br. J. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ceb.2014.01.005","article-title":"Novel Insights into G Protein and G Protein-Coupled Receptor Signaling in Cancer","volume":"27","author":"Degese","year":"2014","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Insel, P.A., Sriram, K., Wiley, S.Z., Wilderman, A., Katakia, T., McCann, T., Yokouchi, H., Zhang, L., Corriden, R., and Liu, D. (2018). GPCRomics: GPCR Expression in Cancer Cells and Tumors Identifies New, Potential Biomarkers and Therapeutic Targets. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00431"},{"key":"ref_46","first-page":"1","article-title":"Somatostatin Receptors","volume":"1616","author":"Stidsen","year":"2003","journal-title":"Biochim. Biophys. Acta BBA\u2014Biomembr."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.yfrne.2013.07.005","article-title":"Somatostatin Receptors: From Signaling to Clinical Practice","volume":"34","author":"Theodoropoulou","year":"2013","journal-title":"Front. Neuroendocrinol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5603\/NMR.2016.0024","article-title":"Radiopharmaceuticals for Somatostatin Receptor Imaging","volume":"19","author":"Maecke","year":"2016","journal-title":"Nucl. Med. Rev."},{"key":"ref_49","first-page":"1704","article-title":"Peptide Receptor Imaging and Therapy","volume":"41","author":"Kwekkeboom","year":"2000","journal-title":"J. Nucl. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002590050034","article-title":"Affinity Profiles for Human Somatostatin Receptor Subtypes SST1-SST5 of Somatostatin Radiotracers Selected for Scintigraphic and Radiotherapeutic Use","volume":"27","author":"Reubi","year":"2000","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"61S","DOI":"10.2967\/jnumed.116.186783","article-title":"Somatostatin Receptor Antagonists for Imaging and Therapy","volume":"58","author":"Fani","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_52","unstructured":"Zhao, J., Zhu, Y., and Chen, M. (2024). Somatostatin Subtype-2 Receptor (SST2R) Targeted Therapeutics and Uses Thereof. (Patent No. WO2024129614 A1)."},{"key":"ref_53","unstructured":"Harris, M.J., Van Dam, E.M., and Mcinnes, L.E. (2024). Dimeric Radiopharmaceuticals, Compositions Thereof and Uses Thereof. (Patent No. WO2024031153 A1)."},{"key":"ref_54","unstructured":"Bhat, A., Smith, N.D., Bakas, N., Noncovich, A., Hudson, A.R., Tran, J.A., Napier, P., and Bravo, Y. (2025). Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof. (Patent No. WO2025137441 A1)."},{"key":"ref_55","unstructured":"Liu, F., Hu, T., and Yang, J. (2025). SSTR Receptor Targeting Radio Compounds and Uses Thereof. (Patent No. WO2025113628 A1)."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Oron-Herman, M., Kirmayer, D., Lupp, A., Schulz, S., Kostenich, G., and Afargan, M. (2023). Expression Prevalence and Dynamics of GPCR Somatostatin Receptors 2 and 3 as Cancer Biomarkers beyond NET: A Paired Immunohistochemistry Approach. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-47877-0"},{"key":"ref_57","unstructured":"Afargan, M., Blum, E., and Salitra, Y. (2022). Conformational Constrained Somatostatin Receptor 3 Peptide Ligands and Their Conjugates and Uses Thereof. (Patent No. WO2022185315 A1)."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2967\/jnumed.119.233031","article-title":"Cholecystokinin 2 Receptor Agonist177 Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study","volume":"61","author":"Rottenburger","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_59","unstructured":"Pokorska-Bocci, A., and Attinger, A. (2023). Method for Predicting the Response of a Patient Diagnosed with Cancer to Treatment and\/or Imaging with a Compound Targeting CCK2-R, and Compound for Use in Methods of Selectively Treating and\/or Imaging Cancer. (Patent No. WO2023051897 A1)."},{"key":"ref_60","unstructured":"Behe, M., and Schibli, R. (2015). Mini-Gastrin Analogue, in Particular for Use in CCK2 Receptor Positive Tumour Diagnosis and\/or Treatment. (Patent No. WO2015067473 A1)."},{"key":"ref_61","unstructured":"Levy, F., and Attinger, A. (2022). Gallium-Labeled Gastrin Analogue and Use in a Method of Imaging CCKB-Receptor-Positive Tumors or Cancers. (Patent No. WO2022023539 A1)."},{"key":"ref_62","unstructured":"Grob, N., Mindt, T.L., Behe, M., Schibli, R., and Valverde, I. (2021). Mono- and Multi-Triazolominigastrins for Targeting of CCK2R-Positive Neoplasms. (Patent No. WO2021165285 A1)."},{"key":"ref_63","unstructured":"Behe, M., Grob, N., Mindt, T.L., and Schibli, R. (2019). Minigastrin Derivates, in Particular for Use in CCK2 Receptor Positive Tumour Diagnosis and\/or Treatment. (Patent No. WO2019057445 A1)."},{"key":"ref_64","unstructured":"G\u00fcnther, T., Holzleitner, N., Wester, H.J., and Lapa, C. (2024). Novel Minigastrin-Derived Cholecystokinin 2 Receptor Binding Molecules for Imaging and Targeted Radiotherapy. (Patent No. WO2024061483 A1)."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/cac2.70063","article-title":"Advances in Radiopharmaceuticals for Cancer Radiotheranostics: CCK2R Targeting as a Paradigm for Translational Innovation","volume":"45","author":"Li","year":"2025","journal-title":"Cancer Commun."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Nock, B.A., Kanellopoulos, P., Chepurny, O.G., Rouchota, M., Loudos, G., Holz, G.G., Krenning, E.P., and Maina, T. (2022). Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCK2R Cancer Theranostic Agents: A Preclinical Study. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14030666"},{"key":"ref_67","unstructured":"Liu, F., and Hu, T. (2024). Dual Receptor Targeting Radioligands and Uses Thereof. (WO2024083224 A1)."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/31269","article-title":"Function of the Chemokine Receptor CXCR4 in Haematopoiesis and in Cerebellar Development","volume":"393","author":"Zou","year":"1998","journal-title":"Nature"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7150\/thno.5760","article-title":"CXCR4 Chemokine Receptor Overview: Biology, Pathology and Applications in Imaging and Therapy","volume":"3","author":"Jacobson","year":"2013","journal-title":"Theranostics"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Yu, J., Zhou, X., and Shen, L. (2023). CXCR4-Targeted Radiopharmaceuticals for the Imaging and Therapy of Malignant Tumors. Molecules, 28.","DOI":"10.3390\/molecules28124707"},{"key":"ref_71","unstructured":"Amodeo, P., Vitale, R., De Luca, S., Scala, S., Castello, G., and Siani, A. (2011). Cyclic Peptides Binding CXCR4 Receptor and Relative Medical and Diagnostic Uses. (Patent No. WO2011092575 A1)."},{"key":"ref_72","unstructured":"Scala, S., and Trotta, A.M. (2021). Radiolabeled Peptides for Non-Invasive Diagnosis and Treatment of CXCR4 Expressing Tumors. (Patent No. WO2021130329 A1)."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"9641","DOI":"10.1021\/acs.jmedchem.7b01062","article-title":"Structure\u2013Activity Relationships and Biological Characterization of a Novel, Potent, and Serum Stable C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonist","volume":"60","author":"Trotta","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1021\/jm049429h","article-title":"Stereoselective Synthesis of [L-Arg-L\/D-3-(2-Naphthyl)Alanine]-Type (E)-Alkene Dipeptide Isosteres and Its Application to the Synthesis and Biological Evaluation of Pseudopeptide Analogues of the CXCR4 Antagonist FC131","volume":"48","author":"Tamamura","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_75","unstructured":"Wester, H.-J., Konrad, M., and Schottelius, M. (2022). CXCR4-Ligands for Diagnostic and Therapeutic Use and Precursors Thereof. (Patent No. WO2022171869 A1)."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Garcia-Recio, S., and Gasc\u00f3n, P. (2015). Biological and Pharmacological Aspects of the NK1-Receptor. BioMed Res. Int., 2015.","DOI":"10.1155\/2015\/495704"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Ebrahimi, S., Mirzavi, F., Aghaee-Bakhtiari, S.H., and Hashemy, S.I. (2022). SP\/NK1R System Regulates Carcinogenesis in Prostate Cancer: Shedding Light on the Antitumoral Function of Aprepitant. Biochim. Biophys. Acta BBA\u2014Mol. Cell Res., 1869.","DOI":"10.1016\/j.bbamcr.2022.119221"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0028-3908(96)00020-2","article-title":"Tachykinin NK1 Receptor Antagonists Act Centrally to Inhibit Ernesis Induced by the Chemotherapeutic Agent Cisplatin in Ferrets","volume":"35","author":"Tattersall","year":"1996","journal-title":"Neuropharmacology"},{"key":"ref_79","unstructured":"Nestor, M., Bengtsson, C., Yngve, U., Begnini, F., Jha, P., and Rosenstr\u00f6m, U. (2025). Substituted 2-Phenylpiperidine Compounds for Use in the Diagnosis, Treatment and\/or Prevention of Cancer. (Patent No. WO2025008409 A2)."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Fridmanis, D., Roga, A., and Klovins, J. (2017). ACTH Receptor (MC2R) Specificity: What Do We Know About Underlying Molecular Mechanisms?. Front. Endocrinol., 8.","DOI":"10.3389\/fendo.2017.00013"},{"key":"ref_81","unstructured":"Zhao, J., Chen, M., Zhu, Y., and Kim, S.H. (2023). Melanocortin Type 2 Receptor (MC2R) Targeted Therapeutics and Uses Thereof. (WO2023219952 A1)."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1124\/pr.110.002774","article-title":"International Union of Basic and Clinical Pharmacology. LXXVII. Kisspeptin Receptor Nomenclature, Distribution, and Function","volume":"62","author":"Kirby","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"E202","DOI":"10.1152\/ajpendo.00517.2010","article-title":"Interactions between Kisspeptin and Neurokinin B in the Control of GnRH Secretion in the Female Rat","volume":"300","author":"Navarro","year":"2011","journal-title":"Am. J. Physiol.-Endocrinol. Metab."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"E296","DOI":"10.1152\/ajpendo.00426.2009","article-title":"A Kisspeptin-10 Analog with Greater in Vivo Bioactivity than Kisspeptin-10","volume":"298","author":"Curtis","year":"2010","journal-title":"Am. J. Physiol.-Endocrinol. Metab."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez Sarmiento, D.Y. (2023). Beyond Reproduction: Exploring the Non-Canonical Roles of the Kisspeptin System in Diverse Biological Systems. Bionatura, 8.","DOI":"10.21931\/RB\/2023.08.03.13"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Sarmiento, D.Y., Rond\u00f3n-Villarreal, P., Scarpelli-Pereira, P.H., and Bouvier, M. (2024). Comprehensive Analysis of Kisspeptin Signaling: Effects on Cellular Dynamics in Cervical Cancer. Biomolecules, 14.","DOI":"10.20944\/preprints202405.1462.v1"},{"key":"ref_87","unstructured":"Liu, J., Zhu, Y., and Xiong, Y. (2024). Kisspeptin Receptor (KISS1R) Targeted Therapeutics and Uses Thereof. (Patent No. WO2024206577 A1)."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0165-6147(99)01357-7","article-title":"Neurotensin and Neurotensin Receptors","volume":"20","author":"Vincent","year":"1999","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/BF02071313","article-title":"Neurotensin Receptors: Binding Properties, Transduction Pathways, and Structure","volume":"15","author":"Vincent","year":"1995","journal-title":"Cell. Mol. Neurobiol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/00000658-200006000-00008","article-title":"Gut Peptide Receptor Expression in Human Pancreatic Cancers","volume":"231","author":"Ehlers","year":"2000","journal-title":"Ann. Surg."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.peptides.2008.04.014","article-title":"Increased Neurotensin Receptor-1 Expression during Progression of Colonic Adenocarcinoma","volume":"29","author":"Gui","year":"2008","journal-title":"Peptides"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1158\/0008-5472.CAN-06-0450","article-title":"Expression of Neurotensin and NT1 Receptor in Human Breast Cancer: A Potential Role in Tumor Progression","volume":"66","author":"Dupouy","year":"2006","journal-title":"Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Dupouy, S., Viardot-Foucault, V., Alifano, M., Souaz\u00e9, F., Plu-Bureau, G., Chaouat, M., Lavaur, A., Hugol, D., Gespach, C., and Gompel, A. (2009). The Neurotensin Receptor-1 Pathway Contributes to Human Ductal Breast Cancer Progression. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0004223"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2967\/jnumed.117.193847","article-title":"177Lu-3BP-227 for Neurotensin Receptor 1\u2013Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results","volume":"59","author":"Baum","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S0022-3565(24)36482-1","article-title":"Biochemical and Pharmacological Activities of SR 142948A, a New Potent Neurotensin Receptor Antagonist","volume":"280","author":"Gully","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_96","unstructured":"Liu, F. (2023). Compounds and Radioligands for Targeting Neurotensin Receptor and Uses Thereof. (Patent No. WO2023158802 A1)."},{"key":"ref_97","unstructured":"Li, Z., and Wu, Z. (2023). Development of NTSR Targeted Agents for Imaging and Therapy Applications. (Patent No. WO2023215778 A1)."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","article-title":"Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, from Heloderma Suspectum Venom. Further Evidence for an Exendin Receptor on Dispersed Acini from Guinea Pig Pancreas","volume":"267","author":"Eng","year":"1992","journal-title":"J. Biol. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nucmedbio.2021.10.001","article-title":"68Ga-Labelled-Exendin-4: New GLP1R Targeting Agents for Imaging Pancreatic \u03b2-Cell and Insulinoma","volume":"102\u2013103","author":"Li","year":"2021","journal-title":"Nucl. Med. Biol."},{"key":"ref_102","unstructured":"Zhu, L., Li, L., Zhao, R., and Kong, F. (2021). Exendin-4 Radioactive Probe Targeting a Glucagon-Like Peptide-1 Receptor, and Preparation Method Thereof. (Patent No. CN113024657 A)."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.2174\/1570159X21666230801140648","article-title":"Magnetic Resonance Imaging and Nuclear Imaging of ParkinsonianDisorders: Where Do We Go from Here?","volume":"22","author":"Savoie","year":"2024","journal-title":"Curr. Neuropharmacol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.plrev.2024.03.007","article-title":"PET Brain Imaging in Neurological Disorders","volume":"49","author":"Xie","year":"2024","journal-title":"Phys. Life Rev."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Doroszkiewicz, J., Groblewska, M., and Mroczko, B. (2022). Molecular Biomarkers and Their Implications for the Early Diagnosis of Selected Neurodegenerative Diseases. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23094610"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Colom, M., Vidal, B., and Zimmer, L. (2019). Is There a Role for GPCR Agonist Radiotracers in PET Neuroimaging?. Front. Mol. Neurosci., 12.","DOI":"10.3389\/fnmol.2019.00255"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s00213-005-2200-z","article-title":"Ionotropic and Metabotropic Glutamate Receptor Structure and Pharmacology","volume":"179","author":"Kew","year":"2005","journal-title":"Psychopharmacology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1146\/annurev.pharmtox.37.1.205","article-title":"Pharmacology and functions of metabotropic glutamate receptors","volume":"37","author":"Conn","year":"1997","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1046\/j.1471-4159.2000.0750889.x","article-title":"Regulation of Neurotransmitter Release by Metabotropic Glutamate Receptors","volume":"75","author":"Cartmell","year":"2000","journal-title":"J. Neurochem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.tips.2008.10.006","article-title":"Activation of Metabotropic Glutamate Receptors as a Novel Approach for the Treatment of Schizophrenia","volume":"30","author":"Conn","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_111","unstructured":"Andr\u00e9s-Gil, J.I., Gool, M.L.M.V., Bormans, G.M.R., and Verbeek, J. (2020). Radiolabelled mGluR2\/3 PET Ligands. (20200306389 A1), U.S. Patent."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2967\/jnumed.116.176628","article-title":"What We Observe In Vivo Is Not Always What We See In Vitro: Development and Validation of 11C-JNJ-42491293, A Novel Radioligand for mGluR2","volume":"58","author":"Celen","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_113","unstructured":"Yuan, G., and Brownell, A.-L. (2023). Chromane Imaging Ligands. (Patent No. WO2023278729 A1)."},{"key":"ref_114","unstructured":"Luc, M., Van Gool, M., Andr\u00e9s-Gil, J.I., Alc\u00e1zar-Vaca, M.J., Bormans, G.M.R., Celen, S.J.L., and Verbeek, J. (2021). Radiolabelled mGluR2 PET Ligands. (20210177995 A1), U.S. Patent."},{"key":"ref_115","unstructured":"Zhang, Z., Zheng, B., Yuan, G., Neelamegam, R., and Brownell, A.-L. (2021). Modulators of Metabotropic Glutamate Receptor 2. (Patent No. WO2021155196 A1)."},{"key":"ref_116","unstructured":"Zhang, Z., Wang, J., Shoup, T.M., and Brownell, A.-L. (2022). Modulators of Metabotropic Glutamate Receptor 4. (20220118117 A1), U.S. Patent."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0024-3205(78)90157-1","article-title":"Multiple Classes of Dopamine Receptors in Mammalian Central Nervous System: The Involvement of Dopamine-Sensitive Adenylyl Cyclase","volume":"23","author":"Kebabian","year":"1978","journal-title":"Life Sci."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/pr.110.002642","article-title":"The Physiology, Signaling, and Pharmacology of Dopamine Receptors","volume":"63","author":"Beaulieu","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"ref_119","first-page":"119","article-title":"Comparison of the Distribution of D-1 and D-2 Dopamine Receptors in the Rat Brain","volume":"2","author":"Wamsley","year":"1989","journal-title":"J. Chem. Neuroanat."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0006-8993(86)90749-3","article-title":"Autoradiographic Localization of D1 Dopamine Receptors in the Rat Brain with [3H]SCH 23390","volume":"375","author":"Savasta","year":"1986","journal-title":"Brain Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/cne.903440109","article-title":"Autoradiographic Distribution of [3H]YM-09151-2, a High-Affinity and Selective Antagonist Ligand for the Dopamine D2 Receptor Group, in the Rat Brain and Spinal Cord","volume":"344","author":"Yokoyama","year":"1994","journal-title":"J. Comp. Neurol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/jlcr.3000","article-title":"Radioligands for the Dopamine Receptor Subtypes","volume":"56","author":"Prante","year":"2013","journal-title":"J. Label. Compd. Radiopharm."},{"key":"ref_123","unstructured":"Mercier, J., Valade, A., Vermeiren, C., Wood, M., and Macquire, R. (2024). Imaging Agents. (20240343737 A1), U.S. Patent."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"MacRitchie, N., Frleta-Gilchrist, M., Sugiyama, A., Lawton, T., McInnes, I.B., and Maffia, P. (2020). Molecular Imaging of Inflammation\u2014Current and Emerging Technologies for Diagnosis and Treatment. Pharmacol. Ther., 211.","DOI":"10.1016\/j.pharmthera.2020.107550"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Calabria, F.F., Guadagnino, G., Cimini, A., and Leporace, M. (2024). PET\/CT Imaging of Infectious Diseases: Overview of Novel Radiopharmaceuticals. Diagnostics, 14.","DOI":"10.3390\/diagnostics14101043"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Glaudemans, A.W.J.M., De Vries, E.F.J., Galli, F., Dierckx, R.A.J.O., Slart, R.H.J.A., and Signore, A. (2013). The Use of 18 F-FDG-PET\/CT for Diagnosis and Treatment Monitoring of Inflammatory and Infectious Diseases. Clin. Dev. Immunol., 2013.","DOI":"10.1155\/2013\/623036"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"10990","DOI":"10.18632\/oncotarget.7770","article-title":"New Pathogen-Specific immunoPET\/MR Tracer for Molecular Imaging of a Systemic Bacterial Infection","volume":"7","author":"Wiehr","year":"2016","journal-title":"Oncotarget"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Mulero, F. (2023). Editorial: ImmunoPET Imaging in Disease Diagnosis and Therapy Assessment. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1231525"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/aps.2011.200","article-title":"Role of G Protein-Coupled Receptors in Inflammation","volume":"33","author":"Sun","year":"2012","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/j.1476-5381.2011.01551.x","article-title":"Pharmacological Modulation of Chemokine Receptor Function","volume":"165","author":"Scholten","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1096\/fj.201500116","article-title":"ECL1i, d(LGTFLKC), a Novel, Small Peptide That Specifically Inhibits CCL2-dependent Migration","volume":"30","author":"Auvynet","year":"2016","journal-title":"FASEB J."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2967\/jnumed.120.244673","article-title":"Targeted PET Imaging of Chemokine Receptor 2\u2013Positive Monocytes and Macrophages in the Injured Heart","volume":"62","author":"Heo","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_133","unstructured":"Liu, Y., Gropler, R., Brody, S., and Kreisel, D. (2020). Methods for Detecting CCR2 Receptors. (20200405889 A1), U.S. Patent."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Uhl\u00e9n, M., Fagerberg, L., Hallstr\u00f6m, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, \u00c5., Kampf, C., Sj\u00f6stedt, E., and Asplund, A. (2015). Tissue-Based Map of the Human Proteome. Science, 347.","DOI":"10.1126\/science.1260419"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1126\/science.1891716","article-title":"Tiffany Cloning of Complementary DNA Encoding a Functional Human Interleukin-8 Receptor","volume":"253","author":"Philip","year":"1991","journal-title":"Science"},{"key":"ref_136","unstructured":"Decker, M., Higuchi, T., and Spatz, P. (2025). 18F-CXCR2 PET Tracer. (Patent No. WO2025149577 A1)."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"6590","DOI":"10.4049\/jimmunol.165.11.6590","article-title":"Stromal Cell-Derived Factor-1-CXC Chemokine Receptor 4 Interactions Play a Central Role in CD4+ T Cell Accumulation in Rheumatoid Arthritis Synovium","volume":"165","author":"Nanki","year":"2000","journal-title":"J. Immunol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.yjmcc.2014.04.021","article-title":"CXCR4 Blockade Induces Atherosclerosis by Affecting Neutrophil Function","volume":"74","author":"Bot","year":"2014","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_139","unstructured":"B\u00e9nard, F., Lin, K.-S., Rousseau, E., Zhang, Z., Kwon, D., Lau, J., Munoz, C.U., Lozada, J., and Perrin, D. (2020). Novel Radiolabelled CXCR4-Targeting Compounds for Diagnosis and Therapy. (Patent No. WO2020210919 A1)."},{"key":"ref_140","unstructured":"B\u00e9nard, F., Lin, K.-S., Zhang, Z., Kwon, D., Perrin, D., Todorovic, M., Lozada, J., and Li, L.L. (2022). Novel CXCR4-Targeting Compounds. (Patent No. WO2022082312 A1)."},{"key":"ref_141","unstructured":"James, M.L., Jackson, I.M., Kalita, M., and Nagy, S.C. (2024). Method for Detecting Innate Immune Action in Vivo Using GPR84-PET. (Patent No. WO2024220480 A2)."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"13526","DOI":"10.1021\/acs.jmedchem.0c00272","article-title":"Discovery of 9-Cyclopropylethynyl-2-((S)-1-[1,4]Dioxan-2-Ylmethoxy)-6,7-Dihydropyrimido [6,1-a]Isoquinolin-4-One (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial","volume":"63","author":"Dupont","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"481","DOI":"10.7150\/thno.4024","article-title":"Radiolabeled Peptides: Valuable Tools for the Detection and Treatment of Cancer","volume":"2","author":"Fani","year":"2012","journal-title":"Theranostics"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1053\/j.semnuclmed.2017.05.007","article-title":"Clinical Applications of Radiolabeled Peptides for PET","volume":"47","author":"Jackson","year":"2017","journal-title":"Semin. Nucl. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.2967\/jnumed.108.053041","article-title":"Peptide-Based Probes for Cancer Imaging","volume":"49","author":"Reubi","year":"2008","journal-title":"J. Nucl. Med."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Krutzek, F., Donat, C.K., Ullrich, M., Zarschler, K., Ludik, M.-C., Feldmann, A., Loureiro, L.R., Kopka, K., and Stadlbauer, S. (2023). Design and Biological Evaluation of Small-Molecule PET-Tracers for Imaging of Programmed Death Ligand 1. Cancers, 15.","DOI":"10.3390\/cancers15092638"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1002\/anie.201707816","article-title":"Small Molecules Drive Big Improvements in Immuno-Oncology Therapies","volume":"57","author":"Huck","year":"2018","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10799890902732823","article-title":"Receptor-Mediated Tumor Targeting with Radiopeptides: Part 1. General Principles and Methods","volume":"29","author":"Eberle","year":"2009","journal-title":"J. Recept. Signal Transduct."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Mansi, R., and Fani, M. (2021). Radiolabeled Peptides for Cancer Imaging and Therapy: From Bench-to-Bedside. Chimia, 75.","DOI":"10.2533\/chimia.2021.500"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1053\/snuc.2001.27045","article-title":"Radiolabeled Peptides in Diagnosis and Therapy","volume":"31","author":"Weiner","year":"2001","journal-title":"Semin. Nucl. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.tips.2009.05.005","article-title":"PET Radiotracers: Crossing the Blood\u2013Brain Barrier and Surviving Metabolism","volume":"30","author":"Pike","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.mibio.2003.09.014","article-title":"Determination of Lipophilicity and Its Use as a Predictor of Blood\u2013Brain Barrier Penetration of Molecular Imaging Agents","volume":"5","author":"Waterhouse","year":"2003","journal-title":"Mol. Imaging Biol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ddtec.2017.11.007","article-title":"Medicinal Chemistry Strategies for PET Tracer Discovery","volume":"25","author":"Schmidt","year":"2017","journal-title":"Drug Discov. Today Technol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/S0006-2952(99)00259-2","article-title":"Effect of D-Amino Acid Substitution on the Stability, the Secondary Structure, and the Activity of Membrane-Active Peptide","volume":"58","author":"Hong","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"149S","DOI":"10.2967\/jnumed.107.045963","article-title":"Tumor Receptor Imaging","volume":"49","author":"Mankoff","year":"2008","journal-title":"J. Nucl. Med."},{"key":"ref_156","first-page":"1012","article-title":"Use of Polyglutamic Acids to Reduce Uptake of Radiometal-Labeled Minigastrin in the Kidneys","volume":"46","author":"Kluge","year":"2005","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1021\/acs.bioconjchem.8b00849","article-title":"Elucidating the Structure\u2013Activity Relationship of the Pentaglutamic Acid Sequence of Minigastrin with Cholecystokinin Receptor Subtype 2","volume":"30","author":"Ritler","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.addr.2016.06.007","article-title":"Peptide-Based Imaging Agents for Cancer Detection","volume":"110\u2013111","author":"Sun","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Nh\u00e0n, N.T.T., Yamada, T., and Yamada, K.H. (2023). Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241612931"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.4155\/fmc.12.75","article-title":"Flexible Or Fixed: A Comparative Review Of Linear And Cyclic Cancer-Targeting Peptides","volume":"4","author":"Roxin","year":"2012","journal-title":"Future Med. Chem."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1021\/cbmi.4c00030","article-title":"Peptide PET Imaging: A Review of Recent Developments and a Look at the Future of Radiometal-Labeled Peptides in Medicine","volume":"2","author":"Shabsigh","year":"2024","journal-title":"Chem. Biomed. Imaging"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1039\/D2MD00397J","article-title":"Peptide-Based Positron Emission Tomography Probes: Current Strategies for Synthesis and Radiolabelling","volume":"14","author":"Failla","year":"2023","journal-title":"RSC Med. Chem."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1021\/ar500233s","article-title":"A Philosophy for CNS Radiotracer Design","volume":"47","author":"Ricq","year":"2014","journal-title":"Acc. Chem. Res."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Zhou, H., Chen, Z., Gao, S., Lian, C., Hu, J., Lu, J., and Zhang, L. (2025). GPR65 Is a Novel Immune Biomarker and Regulates the Immune Microenvironment in Lung Adenocarcinoma. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1572757"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/6\/900\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:24:16Z","timestamp":1781065456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/6\/900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":164,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ph19060900"],"URL":"https:\/\/doi.org\/10.3390\/ph19060900","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]}}}